HealthImaging (1/15, Pearson) reports, “Determination of breast density fluctuates considerably from one exam to the next in any given woman,” which “can both perplex the patient and drive unintended consequences into her care pathway – effects that may be exacerbated by the direct-to-consumer density notifications required by law in (so far) 24 U.S. states.” Additionally, investigators found that “supplemental screening of women with dense breasts does indeed find additional breast cancer, but it also increases false positives.” These findings come from a review published online in the Annals of Internal Medicine.
A group of like-minded women’s health care organizations expressed their disappointment with the United States Preventive Services Task Force (USPSTF or Task Force) for finalizing its draft breast cancer screening recommendations in spite of 2015 legislation mandating a moratorium on implementation. The Task Force chose to publish its guidelines just weeks after Congress passed the legislation that would prevent the recommendations from going into effect until Jan. 1, 2018, adding another layer of confusion for women and physicians.
SBI Immediate Past President, Murray Rebner, MD, FSBI, SBI Board Member Jay Baker, MD, FSBI and SBI Members Rachel Brem, MD, FSBI, Avice O'Connell, MD, FSBI, Susan Harvey, MD, and Wendie Berg, MD, FSBI, warn that the final breast cancer screening guidelines, issued by the U.S. Preventive Services Task Force (USPSTF), will cause the deaths of thousands of women.
The Los Angeles Times (1/12, Kaplan) “Science Now” reports that research suggests that with regard to “breast cancer, improvements in treatment have barely changed the benefit of using mammograms as a screening tool.” The research “explains that the value of early detection depends in part on the effectiveness of treatment.” The findings were published in Annals of Internal Medicine.